Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | HTR1B | P28222 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7257808 | 0.98 | PTGDR2 (0.44) | PTGDR2NAAAEPHX1PTGS2SLC6A2 | |
| SCHEMBL477701 | 0.90 | SLC6A4 (0.42) | PTGDR2NAAAEPHX1SLC6A2SLC6A4 | |
| SCHEMBL9203359 | 0.85 | PTGDR2 (0.44) | PTGDR2NAAAEPHX1PTGS2SLC6A2 | |
| SCHEMBL17417173 | 0.83 | PTGDR2 (0.40) | PTGDR2NAAAEPHX1PTGS2NUDT1 | |
| SCHEMBL7496193 | 0.82 | PTGDR2 (0.41) | PTGDR2NAAAPTGS2SLC6A2SLC6A4 | |
| SCHEMBL9626982 | 0.82 | OPRL1 (0.44) | PTGDR2NAAAEPHX1PTGS2NUDT1 | |
| SCHEMBL29805150 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL12835831 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL677543 | 0.80 | PTGDR2 (0.42) | PTGDR2NAAAPTGS2SLC6A2SLC6A4 | |
| SCHEMBL11265348 | 0.80 | PTGDR2 (0.42) | PTGDR2NAAAPTGS2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109548405-B | Electrodepositable coating compositions with improved crater control | PPG工业俄亥俄公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-109526225-B | Electrodepositable coating compositions with improved crater control | PPG工业俄亥俄公司 | 2021-11-09 | — | — | CN | disclosed |
| US-9828338-B2 | Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
| EP-2970201-A1 | 6-[4-(1 H-IMIDAZOL-2-YL)PIPERIDIN-1 -YL]PYRIMIDIN-4-AMINE DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144836-A2 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143612-A1 | 6-[4-(1 H-IMIDAZOL-2-YL)PIPERIDIN-1 -YL]PYRIMIDIN-4-AMINE DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-8563786-B2 | Method for producing optically active alcohol | MITSUI CHEMICALS, INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-04-12 | — | — | US | disclosed |
| EP-2412694-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | Mitsui Chemicals, Inc. (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-0728018-B1 | New enzymes and prodrugs for ADEPT | WELLCOME FOUND (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-6319702-B1 | NUCLEOTIDE SEQUENCS CODING AN ENZYMATIC POLYPEPTIDE AND CELL TARGETING COMPOUND; FOR USE IN TREATMENT OF CANCER | GLAXO WELLCOME, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6140100-A | CONJUGATE POLYPEPTIDE WHICH IS TISSUE PREFERENTIAL; ANTICARCINOGENIC AGENTS | GLAXO WELLCOME INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0564924-B1 | 2-Oxoethyl derivatives as immunosuppressants | BAYER AG (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5686424-A | FOR TREATING INFLAMMATION | MILES INC. (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0728018-A1 | THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013095-A2 | THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
| EP-0564924-A2 | 2-Oxoethyl derivatives as immunosuppressants | Bayer Corporation (US) | 1993-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | PTGDR2 1270/4885NAAA 1/4885EPHX1 222/4885 |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1A, ADH1C, FHIT | PTGDR2 1786/4885NAAA 2013/4885EPHX1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.